Predicting response to cancer therapy

Immune Checkpoint Inhibitors (ICIs) are successful in 40% of cancer patients but are invasive and time-consuming. Scientists at Israel’s Technion Institute have developed a tool that predicts the response based on the metabolic activity in the immune system cells. (See also here previously)

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *